Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Blockade of immune checkpoint pathways by programmed cell death protein 1 (PD-1) antibodies has demonstrated broad clinical efficacy against a variety of malignancies. Sintilimab, a highly selective, fully human monoclonal antibody (mAb), blocks the interaction of PD-1 and its ligands and has demonstrated clinical benefit in various clinical studies. Here, we evaluated the affinity of sintilimab to human PD-1 by surface plasmon resonance and mesoscale discovery and evaluated PD-1 receptor occupancy and anti-tumor efficacy of sintilimab in a humanized NOD/Shi-scid-IL2rgamma (null) (NOG) mouse model. We also assessed the receptor occupancy and immunogenicity of sintilimab from clinical studies in humans (9 patients with advanced solid tumor and 381 patients from 4 clinical studies, respectively). Sintilimab bound to human PD-1 with greater affinity than nivolumab (Opdivo®, MDX-1106) and pembrolizumab (Keytruda®, MK-3475). The high affinity of sintilimab is explained by its distinct structural binding mode to PD-1. The pharmacokinetic behavior of sintilimab did not show any significant differences compared to the other two anti-PD-1 mAbs. In the humanized NOG mouse model, sintilimab showed superior PD-1 occupancy on circulating T cells and a stronger anti-tumor effect against NCI-H292 tumors. The strong anti-tumor response correlated with increased interferon-γ-secreting, tumor-specific CD8+ T cells, but not with CD4+ Tregs in tumor tissue. Pharmacodynamics testing indicated a sustained mean occupancy of ≥95% of PD-1 molecules on circulating T cells in patients following sintilimab infusion, regardless of infusion dose. Sintilimab infusion was associated with 0.52% (2/381 patients) of anti-drug antibodies and 0.26% (1/381 patients) neutralizing antibodies. These data validate sintilimab as a novel, safe, and efficacious anti-PD-1 mAb for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · cited 1×
“These models have demonstrated that blocking the murine PD-1/PD-L1 axis can result in immune-mediated anti-tumor activity.(22,23) However, the use of syngeneic murine-derived cancer models in immunecompetent mice has limitations because of the intrinsic differences between the murine and human immune systems.”
BackgroundMolecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
Conservation and divergence in the transcriptional programs of the human and mouse immune systems
Shay, T., Jojic, V., Zuk, O., Rothamel, K., Puyraimond-Zemmour, D., Feng, T., Wakamatsu, E., Benoist, C., Koller, D., Regev, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222738110 · Cited by 359 · cited 1×
“However, the use of syngeneic murine-derived cancer models in immunecompetent mice has limitations because of the intrinsic differences between the murine and human immune systems.(24,25) We have shown previously that sintilimab significantly inhibits tumor growth in a human PD-1 knock-in mouse model of colon adenocar…”
Background
Cited by
Humanized mouse models for immuno-oncology research
Chuprin, J., Buettner, H., Seedhom, M. O., Greiner, D. L., Keck, J. G., Ishikawa, F., Shultz, L. D., & Brehm, M. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00721-2 · Cited by 423
Xu, J., Jiang, H., Pan, Y., Gu, K., Cang, S., Han, L., Shu, Y., Li, J., Zhao, J., Pan, H., et al. (2023) · JAMA · doi:10.1001/jama.2023.19918 · Cited by 406
Self-citationYang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.014 · Cited by 390
Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.011 · Cited by 322
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., Chang, Q., Zhang, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.026 · Cited by 227
Metadata
- Authors
- Wang, J., Fei, K., Jing, H., Wu, Z., Wu, W., Zhou, S., Ni, H., Chen, B., Xiong, Y., Liu, Y., Peng, B., Yu, D., Jiang, H., & Liu, J.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2019-09-03
- Volume
- 11
- Issue
- 8
- Pages
- 1443-1451
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2967960429
- Cited by
- 149
- References
- 8
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. https://app.cochat.ai/papers/10.1080/19420862.2019.1654303
- The paper
- Wang, J., Fei, K., Jing, H., Wu, Z., Wu, W., Zhou, S., Ni, H., Chen, B., Xiong, Y., Liu, Y., Peng, B., Yu, D., Jiang, H., & Liu, J. (2019). Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. https://doi.org/10.1080/19420862.2019.1654303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.